JNJ News & Events

Johnson & Johnson announced updated results from the Phase 1/1b CHRYSALIS-2 study evaluating intravenous RYBREVANT in combination with LAZCLUZE in patients with advanced non-small cell lung cancer with atypical epidermal growth factor receptor mutations. The analysis showed encouraging long-term outcomes with RYBREVANT plus LAZCLUZE in this difficult-to-treat population. Median overall survival, a secondary endpoint, was nearly 3.5 years. The primary endpoint of objective response rate was previously reported. These results add to the growing body of evidence demonstrating the potential of RYBREVANT plus LAZCLUZE to deliver durable survival outcomes across both common and atypical EGFR-mutated advanced NSCLC in the first-line setting. Data were presented in an oral session at the 2026 American Society of Clinical Oncology Annual Meeting. "For patients with non-small cell lung cancer harboring atypical EGFR-mutations, first-line treatment decisions are often clouded by uncertainty regarding the efficacy of currently available EGFR tyrosine kinase inhibitors," said Joel Neal, M.D., Ph.D., principal investigator of the Phase 1/1b CHRYSALIS-2 study. "The responses we've seen in this trial suggest the potential for more durable disease control, and the overall survival data reinforce that picture. These long-term outcomes begin to change how we think about treatment options in managing this subtype of lung cancer." Neal is also a Professor of Medicine in the Division of Oncology at Stanford Medicine." "Disease progression and molecular resistance remain critical barriers in EGFR-mutated non-small cell lung cancer," said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. "RYBREVANT-based combinations demonstrate the power of changing the biology by addressing multiple disease drivers from the start rather than relying on single-pathway strategies. With strong outcomes across all known EGFR mutations, this approach is raising the bar for what first-line treatment can achieve."

Johnson & Johnson announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically meaningful and statistically significant improvements in progression-free survival and overall survival with TECVAYLI versus standard of care regimens in patients with relapsed or refractory multiple myeloma treated as early as second line. In a patient population whose myeloma was predominantly refractory to anti-CD38 therapy and lenalidomide, TECVAYLI reduced the risk of disease progression or death by 71% and the risk of death by 40%.1 These data (Abstract #7507) will be presented as an oral session today at the annual American Society of Clinical Oncology Annual Meeting, with simultaneous publication in The New England Journal of Medicine.

Johnson & Johnson announced that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application to include evidence in the TREMFYA label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis. The inclusion of this key outcome reflects that TREMFYA is the only IL-23 inhibitor proven to help stop further structural damage, offering patients with active PsA a first-line treatment option that provides effective symptom control and no new safety signals, while significantly inhibiting irreversible joint damage. "Joint damage associated with active psoriatic arthritis can happen as soon as six months after onset of disease, so it's important to have treatment solutions that can help provide daily symptom relief while also protecting joints from long-term structural damage," said Philip J. Mease, M.D., Director of Rheumatology Research at the Swedish Medical Center/Providence St. Joseph Health and Clinical Professor at the University of Washington School of Medicine in Seattle, WA. "With the inclusion of these findings in the label, we now have stronger clinical evidence that sets TREMFYA apart as a treatment option for patients with active psoriatic arthritis at risk for joint damage."